Literature DB >> 3778812

Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1 alpha,24-dihydroxycholecalciferol.

T Kato, M Rokugo, T Terui, H Tagami.   

Abstract

We treated 11 psoriatic patients with topical 1 alpha,24-dihydroxycholecalciferol, a new synthetic analogue of active vitamin D3. In 10 of 15 tests the lesions cleared completely within 1-4 weeks, although some relapses occurred shortly after cessation of treatment. There were no side-effects. We suggest that 1 alpha, 24(OH)2D3 merits further investigation as a potentially useful topical therapy for psoriasis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3778812     DOI: 10.1111/j.1365-2133.1986.tb06237.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Tacalcitol.

Authors:  D C Peters; J A Balfour
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  The effect of 1,25(OH)2-vitamin D3 on Langerhans cells and contact hypersensitivity in mice.

Authors:  Z Guo; H Okamoto; S Imamura
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

3.  The mRNA expression of the human 1,25-dihydroxyvitamin D3 receptor and the c-myc protooncogene in cultured human keratinocytes.

Authors:  N M Hanafin; K S Persons; M F Holick
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-03       Impact factor: 2.416

4.  In vivo microautoradiography of [3H]1,24(OH)2D3 (tacalcitol) following topical application to normal rats and in vitro metabolism in human keratinocytes.

Authors:  T Ohta; K Okabe; Y Azuma; M Kiyoki
Journal:  Arch Dermatol Res       Date:  1996-04       Impact factor: 3.017

Review 5.  Vitamin D3 and skin diseases.

Authors:  K Kragballe
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

6.  Suppressive activity of vitamin D3 on matrix metalloproteinase production from cholesteatoma keratinocytes in vitro.

Authors:  Hitome Kobayashi; Kazuhito Asano; Ken-ichi Kanai; Harumi Suzaki
Journal:  Mediators Inflamm       Date:  2005-08-31       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.